The use of nanoparticles is transforming pharmaceutical formulation, improving bioavailability and the development of targeted therapies.

consalud.es

The development of new medicines is one of the most complex and costly processes in the pharmaceutical industry. It can take more than ten years from the discovery of a molecule to its market launch, with clinical trials typically lasting between six and seven years. In this context, nanotechnology is emerging as a key tool for accelerating innovation and improving the efficacy of treatments.

Pharmaceutical formulation depends on multiple factors such as pH, solubility, crystalline form and particle size. These parameters directly influence critical aspects of the drug, such as its stability, its ability to dissolve and its bioavailability in the body. In this regard, the manipulation of materials at the nanoscale is opening up new possibilities for optimising the performance of medicines, as outlined in a recent study published in the Journal of Innovations in Applied Pharmaceutical Science.

Nanosizing: improving drug solubility

According to the authors of the study, one of the most widely used techniques is known as nanosizing, which involves reducing the size of the active ingredient’s particles to the nanometre scale. This process increases the drug’s surface area and improves its solubility, thereby facilitating its absorption by the body.

In practice, this makes it possible to increase the bioavailability of poorly soluble medicines, accelerate the onset of therapeutic action and, in some cases, reduce the required doses. These improvements are particularly relevant for the development of new oral formulations and for optimising existing medicines.

Furthermore, the precise characterisation of particle size has become an essential element of quality control in the pharmaceutical industry, as particle size distribution can influence properties such as drug dissolution, stability, or the uniformity of content in each dose.

Nanoparticles for targeted therapies

The use of nanoparticles has also opened up new avenues in the field of targeted drug delivery. According to the study, these systems can act as vehicles capable of transporting therapeutic molecules directly to specific tissues. Among the most widely studied platforms are liposomes, dendrimers and polymeric nanoparticles, which allow active ingredients to be encapsulated and released in a controlled manner within the body.

This strategy is particularly promising in areas such as oncology, where targeted therapies can concentrate treatment on the tumour and reduce side effects in healthy tissues. Furthermore, the properties of nanoparticles have expanded their application in biomedicine and biotechnology.

A cross-cutting technology for the pharmaceutical industry

Nanotechnology has become a general-purpose technology with applications across multiple industrial sectors, from electronics and energy to agriculture and cosmetics. In the healthcare sector, its development has given rise to a specific field known as nanomedicine.

This approach integrates disciplines such as molecular biology, bioengineering and materials science to develop new diagnostic tools, advanced therapies and smart drug delivery systems. Emerging applications include lab-on-a-chip devices, biosensors capable of detecting diseases at an early stage, and nanomaterials used in tissue engineering.

Global investment and regulatory challenges
The potential of nanotechnology has driven billions of dollars of investment in research and development, particularly in the industrialised economies of the Americas, Europe and Asia. However, its development also presents regulatory and scientific challenges.

One of the main challenges, according to the study’s authors, is to precisely control the size and structure of nanoparticles during their production, as small variations can significantly alter their biological properties. Furthermore, researchers are investigating the potential environmental and toxicological effects associated with the use of nanomaterials.

Towards a new generation of medicines
Despite these challenges, the scientific consensus suggests that nanotechnology will play a decisive role in the next generation of medical treatments. From more precise drug delivery systems to personalised therapies based on molecular biology, nano-engineered technologies could redefine the way medicines are designed, manufactured and administered.

In a sector where every breakthrough can translate into years of research and billions in investment, nanotechnology is thus emerging as one of the key drivers of pharmaceutical innovation in the 21st century.